The role of prostanoid receptors in mediating the effects of PGE₃ on human platelet function

• References

• 1 Takai S, Jin D, Kawashima H. et al. Anti-atherosclerotic effects of dihomo- ? -linolenic acid in ApoE-deficient mice. J Atheroscler Thromb 2009; 16: 480-489.
• 2 Gross S, Tilly P, Hentsch D. et al. Vascular wall-produced prostaglandin E₂ exacerbates arterial thrombosis and atherothrombosis through platelet EP3 receptors. J Exp Med 2007; 204: 311-320.
• 3 Singh J, Zeller W, Zhou N. et al. Antagonists of the EP3 Receptor for prostaglandin E₂ are novel antiplatelet agents that do not prolong bleeding. ACS Chem Biol 2009; 04: 115-126.
• 4 Madonna R, Salerni S, Schiavone D. et al. Omega-3 fatty acids attenuate constitutive and insulin-induced CD36 expression through a suppression of PPAR α/γ activity in microvascular endothelial cells. Thromb Haemost 2011; 106: 500-510.
• 5 Del Turco S, Basta G, Lazzarini G. et al. Parallel decrease of tissue factor surface exposure and increase of tissue factor microparticle release by the n-3 fatty acid docosahexaenoate in endothelial cells. Thromb Haemost 2007; 98: 219-219.
• 6 Szymczak M, Murray M, Petrovic N. Modulation of angiogenesis by ?-3 polyunsaturated fatty acids is mediated by cyclooxygenases. Blood 2008; 111: 3514-3521.
• 7 Di Minno MND, Tremoli E, Tufano A. et al. Exploring newer cardioprotective strategies: ω-3 fatty acids in perspective. Thromb Haemost 2010; 104: 664-680.
• 8 Larson MK, Ashmore JH, Harris KA. et al. Effects of omega-3 acid ethyl esters and aspirin, alone and in combination, on platelet function in healthy subjects. Thromb Haemost 2008; 100: 634-641.
• 9 Gajos G, Rostoff P, Undas A. et al. Effects of polyunsaturated omega-3 fatty acids on responsiveness to dual antiplatelet therapy in patients undergoing percutaneous intervention. J Am Coll Cardiol 2010; 55: 1671-1678.
• 10 De Caterina R. n-3 Fatty acids in cardiovascular disease. New Engl J Med 2011; 364: 2439-2450.
• 11 Moertl D, Berger R, Hammer A. et al. Dose-dependent decrease of platelet activation and tissue factor by omega-3 polyunsaturated fatty acids in patients with advanced chronic heart failure. Thromb Haemost 2011; 106: 500-510.
• 12 Holy EW, Forestier M, Richter EK. et al. Dietary alpha-linolenic acid inhibits arterial thrombus formation, tissue factor expression, and platelet activation. Arterioscler Thromb Vasc Biol 2011; 31: 1772-1780.
• 13 Fredman G, Van dyke TE, Serhan CN. Resolvin E1 regulates adenosine diphosphate activation of human platelets. Arterioscler Thromb Vasc Biol 2010; 30: 2005-2013.
• 14 Schmitz G, Ecker J. The opposing effects of n-3 and n-6 fatty acids. Progress in Lipid Res 2008; 47: 147-155.
• 15 Iyú D, Glenn JR, White AE. et al. The role of prostanoid receptors in mediating the effects of PGE₂ on human platelet function. Platelets 2010; 21: 329-342.
• 16 Kuriyama S, Kashiwagi H, Yuhki KI. et al. Selective activation of the prostaglandin E₂ receptor subtype EP2 or EP4 leads to inhibition of platelet aggregation. Thromb Haemost 2010; 104: 796-803.
• 17 Smith JP, Haddad EV, Downey JD. et al. PGE₂ decreases reactivity of human platelets by activating EP2 and EP4. Thromb Res 2010; 126: 23-29.
• 18 Iyú D, Jüttner M, Glenn JR. et al. PGE₁ and PGE₂ modify platelet function through different prostanoid receptors. Prostaglandins Other Lipid Mediat 2011; 94: 9-16.
• 19 Heptinstall S, Espinosa DI, Manolopoulos P. et al. DG-041 inhibits the EP3 receptor – a new target for inhibition of platelet function in atherothrombotic disease. Platelets 2008; 19: 605-613.
• 20 Fabre JE, Gurney ME. Limitations of current therapies to prevent thrombosis: a need for novel strategies. Mol Bio Syst 2010; 06: 305-315.